Regnase-1 upregulation <i>via</i> antisense oligonucleotides alleviates pulmonary hypertension
<title>Extract</title> Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary arterial remodelling, leading to right ventricular failure [1]. Genetic background and environmental factors are thought to be involved in the onset of PAH [2]. Accumulating evidence from multiple studies supports the involvement of various inflammatory cytokines, including interleukin (IL)-6 and IL-1, as extrinsic contributors to the pathogenesis of PAH [3–5].
Authors
- Makoto Okazawa (ORCID: https://orcid.org/0000-0002-8564-0124)
- Kotaro Akaki (ORCID: https://orcid.org/0000-0003-0059-3291)
- K.M. Tse (ORCID: https://orcid.org/0000-0002-3306-2895)
- Saori Umeki-Mizushima
- Akiko Yamagishi
- Osamu Takeuchi (ORCID: https://orcid.org/0000-0002-1260-6232)
- Ryotaro Asano (ORCID: https://orcid.org/0000-0003-0303-6546)
- Yoshikazu Nakaoka (ORCID: https://orcid.org/0000-0002-8404-2587)
- Tadakatsu Inagaki (ORCID: https://orcid.org/0000-0002-2639-199X)
- Xin Ding
Institutions
- Kyoto University (JP)
- Kyoto College of Medical Science (JP)
- National Cerebral and Cardiovascular Center (JP)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2026-07-23
- DOI
- https://doi.org/10.1183/23120541.00912-2026
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- National Cerebral and Cardiovascular Center
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
- Janssen Japan